{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:35:36Z","timestamp":1768462536592,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848016010"],"award-info":[{"award-number":["848016010"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00280-022-04489-1","type":"journal-article","created":{"date-parts":[[2022,11,22]],"date-time":"2022-11-22T08:29:45Z","timestamp":1669105785000},"page":"33-42","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial"],"prefix":"10.1007","volume":"91","clinical-trial-number":[{"clinical-trial-number":"nct03655821","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Nikki","family":"de Rouw","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6399-2604","authenticated-orcid":false,"given":"Ren\u00e9 J.","family":"Boosman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus A.","family":"Burgers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hieronymus. J.","family":"Derijks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berber","family":"Piet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lizza E. L.","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonne","family":"Biesma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda A.","family":"Pruis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sander","family":"Croes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"issue":"Suppl 4","key":"4489_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C et al (2018) Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 29(Suppl 4):192\u2013237. https:\/\/doi.org\/10.1093\/annonc\/mdy275","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"4489_CR2","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","volume":"26","author":"P Baas","year":"2015","unstructured":"Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S et al (2015) Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v31\u2013v39. https:\/\/doi.org\/10.1093\/annonc\/mdv199","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"4489_CR3","doi-asserted-by":"publisher","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","volume":"26","author":"N Girard","year":"2015","unstructured":"Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S, Committee EG (2015) Thymic epithelial tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v40-55. https:\/\/doi.org\/10.1093\/annonc\/mdv277","journal-title":"Ann Oncol"},{"key":"4489_CR4","unstructured":"European Medicine Agency (EMA). ALIMTA EPAR - Product Information. 2017. Available via: https:\/\/www.ema.europa.eu"},{"key":"4489_CR5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00972-1","author":"N de Rouw","year":"2021","unstructured":"de Rouw N, Boosman RJ, Huitema ADR, Hilbrands LB, Svensson EM, Derijks HJ et al (2021) Rethinking the application of pemetrexed for patients with renal impairment: a pharmacokinetic analysis. Clin Pharmacokinet. https:\/\/doi.org\/10.1007\/s40262-020-00972-1","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"4489_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A et al (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24(4):552\u2013562. https:\/\/doi.org\/10.1200\/JCO.2004.00.9720","journal-title":"J Clin Oncol"},{"issue":"4","key":"4489_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-005-0035-2","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK\/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57(4):427\u2013435. https:\/\/doi.org\/10.1007\/s00280-005-0035-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4489_CR8","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s00280-016-3078-7","volume":"78","author":"Y Ando","year":"2016","unstructured":"Ando Y, Hayashi T, Ujita M, Murai S, Ohta H, Ito K et al (2016) Effect of renal function on pemetrexed-induced haematotoxicity. Cancer Chemother Pharmacol 78(1):183\u2013189. https:\/\/doi.org\/10.1007\/s00280-016-3078-7","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4489_CR9","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1016\/j.cllc.2015.01.001","volume":"16","author":"CY Chen","year":"2015","unstructured":"Chen CY, Lin JW, Huang JW, Chen KY, Shih JY, Yu CJ et al (2015) Estimated creatinine clearance rate Is associated with the treatment effectiveness and toxicity of pemetrexed as continuation maintenance therapy for advanced nonsquamous non-small-cell lung cancer. Clin Lung Cancer 16(6):e131\u2013e140. https:\/\/doi.org\/10.1016\/j.cllc.2015.01.001","journal-title":"Clin Lung Cancer"},{"key":"4489_CR10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2019.08.012","volume":"121","author":"S Visser","year":"2019","unstructured":"Visser S, Koolen SLW, de Bruijn P, Belderbos HNA, Cornelissen R, Mathijssen RHJ et al (2019) Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: a prospective cohort study. Eur J Cancer 121:64\u201373. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.012","journal-title":"Eur J Cancer"},{"issue":"1","key":"4489_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16(1):31\u201341. https:\/\/doi.org\/10.1159\/000180580","journal-title":"Nephron"},{"issue":"5","key":"4489_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365\u2013376. https:\/\/doi.org\/10.1093\/jnci\/85.5.365","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4489_CR13","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","volume":"57","author":"JE Latz","year":"2006","unstructured":"Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57(4):401\u2013411. https:\/\/doi.org\/10.1007\/s00280-005-0036-1","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4489_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s00280-019-04006-x","volume":"85","author":"N de Rouw","year":"2020","unstructured":"de Rouw N, Visser S, Koolen SLW, Aerts J, van den Heuvel MM, Derijks HJ et al (2020) A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Cancer Chemother Pharmacol 85(1):231\u2013235. https:\/\/doi.org\/10.1007\/s00280-019-04006-x","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"4489_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/FTD.0000000000000672","volume":"42","author":"E van den Hombergh","year":"2020","unstructured":"van den Hombergh E, de Rouw N, van den Heuvel M, Croes S, Burger DM, Derijks J et al (2020) Simple and rapid quantification of the multi-enzyme targeting antifolate pemetrexed in human plasma. Ther Drug Monit 42(1):146\u2013150. https:\/\/doi.org\/10.1097\/FTD.0000000000000672","journal-title":"Ther Drug Monit"},{"key":"4489_CR16","unstructured":"R Core Team (2020). R: a language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria. URL https:\/\/www.R-project.org\/"},{"issue":"9","key":"4489_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150(9):604\u2013612. https:\/\/doi.org\/10.7326\/0003-4819-150-9-200905050-00006","journal-title":"Ann Intern Med"},{"issue":"5","key":"4489_CR18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1002\/cpt.2529","volume":"111","author":"N de Rouw","year":"2022","unstructured":"de Rouw N, de Boer M, Boosman RJ, van den Heuvel MM, Burger DM, Lieverse JE et al (2022) The pharmacoeconomic benefits of pemetrexed dose individualization in patients with lung cancer. Clin Pharmacol Ther 111(5):1103\u20131110. https:\/\/doi.org\/10.1002\/cpt.2529","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"4489_CR19","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1007\/s00520-014-2534-3","volume":"23","author":"M Kimura","year":"2015","unstructured":"Kimura M, Naito T, Kenmotsu H, Taira T, Wakuda K, Oyakawa T et al (2015) Prognostic impact of cancer cachexia in patients with advanced non-small cell lung cancer. Support Care Cancer 23(6):1699\u20131708. https:\/\/doi.org\/10.1007\/s00520-014-2534-3","journal-title":"Support Care Cancer"},{"issue":"1","key":"4489_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/1759-7714.12910","volume":"10","author":"R Zhu","year":"2019","unstructured":"Zhu R, Liu Z, Jiao R, Zhang C, Yu Q, Han S et al (2019) Updates on the pathogenesis of advanced lung cancer-induced cachexia. Thorac Cancer 10(1):8\u201316. https:\/\/doi.org\/10.1111\/1759-7714.12910","journal-title":"Thorac Cancer"},{"issue":"11","key":"4489_CR21","doi-asserted-by":"publisher","first-page":"2842","DOI":"10.1200\/jco.1995.13.11.2842","volume":"13","author":"DA Rinaldi","year":"1995","unstructured":"Rinaldi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR et al (1995) Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13(11):2842\u20132850. https:\/\/doi.org\/10.1200\/jco.1995.13.11.2842","journal-title":"J Clin Oncol"},{"issue":"5","key":"4489_CR22","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s002800050992","volume":"44","author":"DA Rinaldi","year":"1999","unstructured":"Rinaldi DA, Kuhn JG, Burris HA, Dorr FA, Rodriguez G, Eckhardt SG et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44(5):372\u2013380. https:\/\/doi.org\/10.1007\/s002800050992","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4489_CR23","first-page":"605","volume":"4","author":"AC McDonald","year":"1998","unstructured":"McDonald AC, Vasey PA, Adams L, Walling J, Woodworth JR, Abrahams T et al (1998) A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Clin Cancer Res 4(3):605\u2013610","journal-title":"Clin Cancer Res"},{"key":"4489_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33721","author":"RJ Boosman","year":"2021","unstructured":"Boosman RJ, Dorlo TPC, de Rouw N, Burgers JA, Dingemans AC, van den Heuvel MM et al (2021) Toxicity of pemetrexed during renal impairment explained\u2013implications for safe treatment. Int J Cancer. https:\/\/doi.org\/10.1002\/ijc.33721","journal-title":"Int J Cancer"},{"key":"4489_CR25","doi-asserted-by":"publisher","first-page":"7719","DOI":"10.12659\/msm.912999","volume":"24","author":"Y Yang","year":"2018","unstructured":"Yang Y, Wang X, Tian J, Wang Z (2018) Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate. Med Sci Monit 24:7719\u20137726. https:\/\/doi.org\/10.12659\/msm.912999","journal-title":"Med Sci Monit"},{"issue":"3","key":"4489_CR26","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1470-2045(11)70339-4","volume":"13","author":"CP Belani","year":"2012","unstructured":"Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F et al (2012) Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. Lancet Oncol 13(3):292\u2013299. https:\/\/doi.org\/10.1016\/S1470-2045(11)70339-4","journal-title":"Lancet Oncol"},{"issue":"11","key":"4489_CR27","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1097\/JTO.0b013e318267cf84","volume":"7","author":"C Gridelli","year":"2012","unstructured":"Gridelli C, de Marinis F, Pujol JL, Reck M, Ramlau R, Parente B et al (2012) Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Thorac Oncol 7(11):1713\u20131721. https:\/\/doi.org\/10.1097\/JTO.0b013e318267cf84","journal-title":"J Thorac Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04489-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:20:45Z","timestamp":1744158045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["4489"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04489-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nikki de Rouw, Rene Boosman, Sjaak Burgers, Alwin Huitema, Hieronymus Derijks, David Burger, Bonne Biesma, Melinda Pruis Sander Croes, Michel van den Heuvel and Rob ter Heine declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Anne-Marie Dingemans: received financial support from advisory boards Sanofi, Amgen, Bayer, Eli-Lilly and Roche and as lecturer from Jansen, Pfizer and AstraZeneca. Outside the submitted work. Berber Piet: is\/was a member of the advisory boards of Takeda, Bristol Meyer Squibb and received lecturer fees from Astra Zeneca and Pfizer, outside the submitted work. Lizza Hendriks: received re-search funding from Roche, Boehringer-Ingelheim, AstraZeneca and Takeda (all to the institution); is\/was a member of the advisory boards for Boehringer-Ingelheim, BMS, Eli-Lilly, Roche, Pfizer, Takeda, MSD and Amgen (all institutional, except once for Roche); received travel and conference reimbursements from Roche; provided funded mentorship sessions with key opinion leaders from AstraZeneca, received fees for webinars\/medtalks from AstraZeneca and funded interview sessions from Roche (to the institution); is a local principal investigator in clinical trials from AstraZeneca, Novartis, BMS, MSD, Merck, GSK, Takeda, Blueprint, Roche, Janssen Pharmaceuticals and Miroti. All outside the submitted manuscript. Daphne Dumoulin: received payment for presentations of MSD, Roche, Astra Zeneca, Novartis, BMS. Received support for attending a congress paid by Novartis, outside the submitted work. Ron Mathijssen: received grants from Astellas, Bayer, Boehringer-Ingelheim, Cristal Therapeutics, Pamgene, Pfizer, Novartis, Servier and Roche, personal fees from Novartis and Servier and holds a patent from Pamgene, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approved by the medical ethics committee (Commissie Mensgebonden Onderzoek Regio Arnhem Nijmegen, Nijmegen, The Netherlands, (Clinicaltrials.gov identifier: NCT03655821)).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained for all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publications"}}]}}